Increased ketoacidosis from co administration of glucose-lowering drugs and Metformin: a post-marketing report study
Abstract
ABSTRACT: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have become widely used not only for glycemic control but also for their protective cardiovascular effects. However, concerns about adverse events including diabetic ketoacidosis and kidney damage, have gained attention, since these agents are used both as a monotherapy and in combination with metformin. In this study, we analyzed 170,000 adverse event reports submitted to the FDA Adverse Event Reporting System for diabetic ketoacidosis (DKA), kidney injury, and lethal outcomes. Reporting odds ratios (RORs) and 95% confidence intervals (CI) revealed substantial variation in adverse event profiles across the six treatments under study. Canagliflozin shows the highest numbers on kidney damage (14.6%) of all SGLT2i monotherapies. Combination with metformin reduces it slightly (14.3%), but results in significantly elevated ketoacidosis (from 15.4% to 22.3%). Empagliflozin adverse effect profile is different, the metformin combination does not change the reported risk of kidney damage, but dramatically increases ketoacidosis from 14.7% to 27.9%, the highest number of all SGLT2i’s and their combinations. Notably, the DKA risk of each the three combinations exceeded the same parameter for a corresponding SGLT2i monotherapy of metformin alone. Metformin alone, on the other, is not associated with ketoacidosis (<1.1%), but has a high reported risk of death (12.7%) and kidney damage (18.7%), while adding any SGLT2i to the…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.